A Phase 3, multicenter, randomized, open-label, sponsor-blinded study to evaluate REGN7508, a Factor XI monoclonal antibody, versus apixaban and enoxaparin for prophylaxis of venous thromboembolism following elective total knee arthroplasty (ROXI-APEX).

A Phase 2 study to evaluate the efficacy and safety of TRL1068 for the treatment of chronic prosthetic joint infection of the knee or hip without exchange arthroplasty.